






































Tumor necrosis factor antagonists for paradoxical
inflammatory reactions in the central nervous
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Case report and review
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Abstract
Rationale:Paradoxical reaction/immune reconstitution inflammatory syndrome is common in patients with central nervous system
tuberculosis. Management relies on high-dose corticosteroids and surgery when feasible.
Patient concern: We describe 2 cases of HIV-negative patients with corticosteroid-refractory paradoxical reactions of central
nervous system tuberculosis.
Diagnoses: The 2 patients experienced clinical impairment shortly after starting therapy for TB, and magnetic resonance imaging
showed the presence of tuberculomas, leading to the diagnosis of a paradoxical reaction.
Interventions: We added infliximab, an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, to the dexamethasone.
Outcomes: Both patients had favorable outcomes, 1 achieving full recovery but 1 suffering neurologic sequelae.
Lessons: Clinicians should be aware of the risk of paradoxical reactions/immune reconstitution inflammatory syndrome when
treating patients with tuberculosis of the central nervous system and should consider the prompt anti-TNF-a agents in cases not
responding to corticosteroids.
Abbreviations: ADA = adenosine deaminase activity, BAS = bronchoalveolar aspirate, CNS-TB = central nervous system
tuberculosis, CSF= cerebrospinal fluid, HIV= human immunodeficiency virus, IRIS= immune reconstitution inflammatory syndrome,
MRI = magnetic resonance image, PCR = polymerase chain reaction, PR = paradoxical reaction, TB = tuberculosis, TNF = tumor
necrosis factor, WBC = white blood cell.
Keywords: adalimumab, case report, central nervous system tuberculosis, immune reconstitution inflammatory syndrome,
infliximab, intracranial tuberculomas, paradoxical reaction, thalidomide, TNF antagonists
1. Introduction
Clinical deterioration following initial improvement with anti-
tuberculosis therapy in central nervous system tuberculosis
(CNS-TB) is a serious complication causing high mortality and
disability.[1] This paradoxical reaction (PR) is particularly
common in patients infected with the human immunodeficiency
virus (HIV); the paradoxical immune reconstitution inflammato-
ry syndrome (IRIS), which is triggered by starting antiretroviral
therapy and the secondary immune restoration.[2,3] Treatment of
PR/IRIS comprises the administration of high doses of corticoste-
roids, with or without surgery, but success rates are non-well
known.
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High levels of tumor necrosis factor (TNF)-a, a cytokine that
plays a central role in acute inflammation and granuloma
formation,[4] have been found in the cerebrospinal fluid (CSF) of
patients with CNS-TB who develop PR/IRIS.[3,5] As such, there
has been an increase in the number of case reports of CNS-TB
with PR/IRIS that have been successfully treated with anti-TNF
antagonists.[6–22] In this article, we report 2 cases of CNS-TB that
developed PR and were treated successfully with infliximab and




A 53-year-old, HIV-negative female from Dominican Republic
who had been diagnosed with sarcoidosis (affecting the lungs,
lymph nodes, and kidneys) 2 years earlier and receiving
immunosuppressive therapy with tacrolimus and mycopheno-
late, who was admitted to another hospital in July 2015 because
of lymphocytic meningitis and a high adenosine deaminase
(ADA) level.Mycobacterium tuberculosis grew in both a CSF and
a bronchoalveolar aspirate (BAS). Magnetic resonance imaging
(MRI) of the brain without gadolinium contrast revealed no
relevant findings. Treatment was initiated with rifampin,
isoniazid, pyrazinamide, and ethambutol, plus dexamethasone
16mg/day. Six weeks later, susceptibility testing showed
resistance to isoniazid, which was substituted for moxifloxacin.
Cycloserine was also added and tapering of the dexamethasone
dose was started.
Five weeks later, in September 2015, she presented with a
generalized tonic-clonic seizure. A second MRI without gadolin-
ium contrast showed multiple infra- and supra-tentorial lesions
consistent with tuberculomas (Fig. 1A), plus an infarct of the
basal ganglia (not shown). CSF analysis showed a shift toward
Figure 1. Magnetic resonance imaging of case 1. Axial and sagittal fluid-attenuated inversion recovery images without gadolinium (A) and axial and coronal T1-
weighted images with gadolinium (B) performed 5 (September 2015) and 8 weeks (October 2015) respectively after starting tuberculosis treatment, showing
multiple supra-and infratentorial lesions, distributed in the brain parenchyma and subarachnoid space. Axial and sagittal scans without gadolinium (C), taken after 6
weeks after receiving a three-dose course of infliximab, showing complete resolution of the tuberculomas.
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polymorphonuclear cell predominance, and culture for myco-
bacteria was negative. Cycloserine was stopped and the high
doses of dexamethasone were restarted. Following slight
improvement in her clinical condition, the patient was referred
to our hospital.
On admission, the patient was oriented and alert. She reported
having a headache and instability when walking. She had slight
dysmetria in the finger-to-nose test, dysdiadochokinesis, distal
tremor and was unable to perform tandem gait. An MRI with
gadolinium on admission revealed multiple (>50) supra- and
infratentorial lesions distributed in the brain parenchyma and
subarachnoid space. There was evidence of leptomeningeal
enhancement involving cranial nerves III, V, VI, VII, both
cerebral middle cerebral arteries, the prepontine and interpe-
duncular cisterns, the vermis and cerebellar folia, and the mild-
enlarged ventricular system (Fig. 1B). CSF analysis showed a
white blood cell (WBC) count of 380/mm3 (74% lymphocytes);
protein, 169mg/dL; glucose, 30mg/dl; and ADA 0.35mkat/L
(normal <0.15mkat/L). A Polymerase chain reaction (PCR) for
M. tuberculosis, performed with the Xpert MTB/RIF (Cepheid,
Sunnyvale, USA), and culture were negative. After an attempt
with higher doses of dexamethasone (24mg/d) and rifampin 900
mg/d plus linezolid 600mg/day without improvement, infliximab
300mg/kg was tried, and the patient made a dramatic recovery
within the first 48hours of therapy. Two additional doses of
infliximab were given at 2 and 6 weeks apart. The MRI without
gadolinium contrast, taken at the original hospital following all 3
doses of infliximab, showed complete resolution of the tuber-
culomas (Fig. 1C), but with residual infarct in the vermis and
basal ganglia. Dexamethasone was subsequently tapered, and she
completed a 12-month course of anti-tuberculosis treatment. In
September 2017, she suffered a subarachnoid hemorrhage due to
rupture of an aneurysm at the bifurcation of the right middle
cerebral artery, but there was no evidence of active TB. Two years
later she underwent kidney transplant and she is currently under
immunosuppressive therapy.
2.2. Case 2
A 19-year-old, HIV-negative male from Pakistan who was being
evaluated in another hospital because of fever and enlarged
abdominal lymph nodes, and who was subsequently admitted in
September 2017 because of headaches and fever. The initial CSF
exam showed a WBC count of 304/mm3 (96% lymphocytes);
protein, 289mg/dl; glucose 46.9mg/dl; and ADA 0.33mkat/L. A
PCR for M. tuberculosis (Xpert MTB/RIF [Cepheid, Sunnyvale,
USA]) was negative, as was the culture for mycobacteria. The
QuantiFERON-TB Gold In-Tube assay (Qiagen, Hilden,
Germany) was positive. With the presumptive diagnosis of
disseminated and CNS-TB, treatment with rifampin, isoniazid
and ethambutol plus Dexamethasone was initiated. His clinical
condition deteriorated over the following 24hours and he was
referred to our hospital.
On hospital admission, the patient was drowsy but was
responsive to verbal stimuli, and he had neck stiffness and
diplopia. The MRI showed leptomeningeal enhancement,
predominantly at the basal cisterns, and enhancement of the
III, V, VI, VII, and VIII cranial nerves (Fig. 2A). Study of the CSF
for syphilis, brucella, and cryptococcus were negative, as were as
conventional cultures, and cytological examination revealed no
atypical cells. A HIV ELISA test was negative. Moxifloxacin was
added to his treatment according to the protocol for initial
treatment of CNS-TB at our institution, and he was discharged
under treatment for TB plus dexamethasone 12mg/day.
Four weeks later, the patient presented with unsteady gait and
weakness of his right lower limb. The MRI showed global
impairment of the initial leptomeningeal enhancement, new
parasagittal frontal brainstem tuberculomas (Fig. 2B), and left
pontine and right thalamic infarcts. CSF exam showed no
relevant changes, except in his WBC (50% polymorphonuclear).
Given the neurologic impairment despite adjunctive dexametha-
sone, we gave a 3mg/kg dose of infliximab, which resulted in
clinical improvement of his gait. He was discharged pending the
administration of 2 more doses of infliximab. An MRI 6 weeks
after the last dose of infliximab showed a marked reduction in
both the leptomeningeal enhancement and the tuberculomas
(Fig. 2C).
A few weeks later, when tapering the dexamethasone dose, he
developed dizziness and right ear deafness. Otorhinolaryngology
consultation revealed that he had suffered an irreversible lesion of
the right VIII cranial nerve. In July 2018, on the eleventh month
of TB treatment, and 1 month after dexamethasone had been
discontinued, a follow-up MRI showed obstructive triventricular
hydrocephalous secondary to a tuberculoma blocking the
aqueduct of Silvius (Fig. 2D, Fig. 3A, and 3B). A second course
of 3 doses of infliximab was administered, and the MRIs
performed after treatment showed complete resolution of the
hydrocephalous and the near-disappearance of the tuberculoma
(Fig. 2E). He completed a 12-month course of treatment for the
TB, and inMarch 2020 (18months after stopping treatment), the
patient is cured with residual deafness of the right ear.
3. Literature review
We conducted a systematic review looking for cases of PR/IRIS
associated with CNS-TB that had been treated with TNF-a
antagonist. We searched the NCBI databases using the following
search strategy: “central nervous system tuberculosis OR
intracranial tuberculoma OR meningeal tuberculosis AND
immune reconstitution inflammatory syndrome OR immune
reconstitution syndrome OR paradoxical reaction AND inflix-
imab OR adalimumab OR etanercept OR thalidomide.”We also
reviewed citations of the main articles to retrieve additional
publications, and we excluded citations for non-human studies,
reviews, and opinion articles.
We identified 17 publications reporting 42 cases; of these, 26
were reported in case reports or case series[6–19,21,22] and 16 were
reported in a single prospective observational study.[20] We
excluded one case that was reported in 2 publications, resulting in
41 cases being included (Table 1). Here we describe the
demographics, PR/IRIS characteristics, treatment, and main
outcomes of the 43 cases (41 from the literature and the 2
reported here) (Table 2). In total, 13 were adults treated with the
monoclonal anti-TNF-a antibody antagonists infliximab, adali-
mumab, or thalidomide, and 30 were children treated with
thalidomide. All but 2 patients (1 adult and 1 child) were treated
with corticosteroids as adjunctive treatment to anti-TB therapy.
The regimens used for PR/IRIS treatment varied greatly in dose
and duration. Infliximab was given at doses ranging from 2.5 to
10mg/kg, 3 doses one month apart (4 cases), 1 initial dose
followed by 2 additional doses 2 and 4 weeks apart (2 cases), a
single dose (1 case) and the dose and duration were unknown in
one case. Adalimumab was given at a dose of 40mg 2 weeks
apart, 2 (1 case) and 4 weeks apart (1 case). Regarding
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Figure 2. Axial and coronal contrast-enhanced T1-weighted magnetic resonance images of case 2. At diagnosis (September 2017): extraparenchymal enhancing
lesion on the right ambient cistern infiltrating the right superior colliculus (A). Six weeks later (November 2017): appearance of new tuberculomas in midbrain
tegmentum, suprasellar cisterns and right temporal uncus (B). After 3 weeks of a three-dose course of infliximab (February 2018): Remarkable reduction of
tuberculomas and leptomeningeal enhancement (C). On the eleventh month of tuberculosis treatment (July 2018): obstructive hydrocephalus secondary to mass
effect over Silvius aqueduct (D). And 3 months after discontinuation of tuberculosis treatment (December 2018): Mild leptomeningeal enhancement, with resolution
of the mass effect (E).
Figure 3. Detailed axial (A) and coronal (B) contrast-enhanced T1-weighted magnetic resonance images showing enlargement of III ventricle and temporal lateral
ventricle horns (arrows) due to obstructive hydrocephalus secondary to mass effect over Silvius aqueduct (arrowhead).
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Table 1
Summary of the 17 publications on paradoxical reaction/immune reconstitution inflammatory syndrome of central nervous system
tuberculosis treated with TNF-a antagonists.
Study (Reference), Year Country N Children (<18 years) Underlying disease TNF inhibitor
Blackmore,[6] 2008 USA 1 – None Infliximab
Lee,[7] 2012 South Korea 1 – None Adalimumab
Jaimes-Hernandez,[8] 2012 Mexico 1 – Juvenile idiopathic arthritis Infliximab
Vandecasteele,[9] 2012 Belgium 1 – HLA-B27 Spondyloarthropathy Infliximab
Molton,[10] 2015 Singapore 2 – None Infliximab
Lwin,[11] 2018 Australia 1 – HIV Infliximab & adalimumab
Schoeman,[12] 2001 South Africa 1 1 Underweight Thalidomide
Roberts,[13] 2003 UK 2 – None Thalidomide
Stefan,[14] 2009 South Africa 1 1 Acute lymphoblastic leukemia Thalidomide
Schoeman,[15] 2006 South Africa 4 4 None Thalidomide
Schoeman,[16] 2010 South Africa 3 3 None Thalidomide
van Toorn,[17] 2012 South Africa 3 3 HIV Thalidomide
de la Riva,[18] 2013 Spain 1 – None Thalidomide
Fourcade,[19] 2014 France 1 – HIV Thalidomide
van Toorn,[20] 2015 South Africa 16 16 4/16 HIV infection Thalidomide
Viel-Thériault,[21] 2016 Canada 1 1 None Thalidomide
Caraffa,[22] 2018 Italy 1 1 None Thalidomide
CNS-TB = central nervous system tuberculosis; PR/IRIS = paradoxical reaction/immune reconstitution inflammatory syndrome, TNF-a = tumor necrosis factor alpha.
Table 2
Characteristics and outcomes of paradoxical reaction/immune reconstitution inflammatory syndrome associated with central nervous
tuberculosis in 43 patients treated with TNF-a antagonists.
Adults (n=13) Children (n=30)
Gender, male, n/N (%) 3 / 12 (25) 14/29 (48.3)
Age, median (range) 40 years (19–63) 6 years (8 months-14 years)
HIV infection, n/N (%) 2/13 (15.4) 7/30 (23.3)
Definite diagnosis of CNS-TB, n/N (%) 8/13 (61.5) 10/26 (38.5)
Adjunctive treatment with corticosteroids, n/N (%) 12/13 (92.3) 29/30 (96.7)
Dexamethasone 7/12 (58.3) 1/29 (3.4)
Prednisolone/prednisone/methylprednisolone 4/12 (33.3) 22/29 (75.9)
Type not specified 1/12 (8.3) 1/29 (3.4)
Form of PR/IRIS, n/N (%)
Enlargement of existing or appearance of new tuberculomas 6/13 (46.2) 25/30 (83.3)
Abscesses – 4/30 (13.3)
Hydrocephalus (impairment) 1/13 (7.7) 1/30 (3.3)
Infarcts/vasculitis 4/13 (30.8) 3/30 (10.0)
Leptomeningeal enhancement (increase) 2/13 (15.4) 7/30 (23.3)
Duration of TB treatment before PR/IRIS, median (range) 1 month (10 days to 5 months) 1 month (3 days to 6 months)
Duration of ART therapy before IRIS, median (range) 2 & 3 weeks respectively 3.5 days (2 to 7 days)







Thalidomide 4/13 (30.8) 30/30 (100)
Clinical Response, n/N (%)
Improvement 13/13 (100) † 25/30 (83.3)
No response – 2/30 (6.7)
Not assessable – 2/30 (6.7)
Outcome, n/N (%)
Alive/full recovery 4/13 (30.8) 17/30 (56.7)
Alive/sequelae 7/13 (53.8) 7/30 (23.3)
Dead 1/13 (7.7) 2/30 (6.7)
Still on treatment 1/13 (7.7) 2/30 (6.7)
Unknown – 2/30 (6.7)
∗
One patient received Infliximab first and then Adalimumab.
† One patient responded to Adalimumab after failing with Infliximab.
ART = antiretroviral therapy, CNS-TB = central nervous system tuberculosis, n/N = number with the condition/number for who the condition is known, PR/IRIS = paradoxical reaction/immune reconstitution
inflammatory syndrome, TNF-alpha = tumor necrosis factor alpha.
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thalidomide, doses ranged from 1 to 24mg/kg/day (27 cases), and
100mg given twice a day (1 case) or once a day (1 case). The
duration of thalidomide treatment was consistently higher than
that of either infliximab or adalimumab, ranging from 2 to 9
months (median 5 months) in 28 cases (one patient died after 2
weeks of treatment).
Overall, 38 (83.5%) cases improved, of which 13 were adults
and 25 were children. Although most children improved
progressively within weeks to months after starting therapy, 2
children did not respond and we could not ascertain the clinical
response in another 2. Twenty four children (80.0%) survived
and 56.7% experienced full recovery. Among the 13 adults, 11
(84.6%) were alive after treatment or a variable follow-up, but
53.8% of these were cured with sequelae of some type. One
patient who initially responded died after 9 months from an
intracerebral hemorrhage secondary to rupture of friable arterial
collaterals.
4. Discussion
This review shows that there is encouraging evidence on the
potential benefit of TNF-a antagonists for managing PR/IRIS in
CNS-TB, without compromising microbiological cure. Indeed,
treatment with these agents improved the clinical conditions of
most patients after unsuccessful treatment with corticosteroids.
Much of the mortality and disability caused by CNS-TB can be
attributed to the harmful effect of the immune-mediated
inflammatory response of the host trying to contain M.
tuberculosis. Inflammation is believed to be enhanced by the
exposure of excess M. tuberculosis antigens to the immune
system during anti-TB therapy, which in turn would cause a
disproportionate response and its clinical expression in form of
PR.[23,24] In HIV co-infected patients, starting antiretroviral
therapy will trigger this response in a patient receiving TB
treatment. It is entirely plausible that amplification of the
inflammatory response takes place in most patients, if not all, and
that PR/IRIS represents an extreme of this clinical expression.
Whereas corticosteroids would be sufficient to control the
inflammatory response in most patients, rendering the process
clinically silent, others would develop a more extreme clinical
syndrome of PR/IRIS in which corticosteroids alone are
insufficient. In fact, although adjunctive treatment with cortico-
steroids has been shown to reduce mortality in patients with
CNS-TB,[25] PR/IRIS still occurs in 31.2% to 56.0% of non-HIV-
infected[26,27] and in 47% HIV-infected patients.[28]
The pathogenicity of the PR/IRIS is poorly understood. TNF-a,
a pro-inflammatory cytokine, is mainly produced by monocytes
and macrophages and has a central role in the immune response
toM. tuberculosis by recruiting immune cells, enhancing the anti-
TB activity of macrophages, and promoting granuloma forma-
tion.[4] It has been postulated that sustained immune activation in
the CSF causes the disproportionate inflammatory response that
leads to PR/IRIS. Consistent with this, higher levels of TNF-a
have been found in the CSF of patients with CNS-TB compared
with that of healthy controls,[5] and research has shown that the
TNF-a to interferon gamma ratio in CSF is highly predictive of
IRIS in HIV patients with CNS-TB.[28] Furthermore, thalido-
mide, a potent TNF-a produced by stimulated monocytes, has
been shown to reduce TNF-a levels in the CSF of rabbits with TB
meningitis.[29] Therefore, the putative mechanism of action of
anti-TNF agents in PR/IRIS would seem straightforward, and
reduction of TNF-a levels in the CSF may be expected. However,
available data give conflicting results. In a prospective study of
CNS-TB in HIV-negative patients, there was no correlation
between either basal TNF-a levels or changes in CSF TNF-a
levels and the development of PR.[30] In addition, in a clinical trial
of CNS-TB in children, adjunctive thalidomide did not
significantly lower TNF-a levels in the CSF compared to
placebo.[31] Because thalidomide is also a co-stimulator of
T-cells, which also produce TNF-a, its immunomodulatory effect
may be driven by achieving a balance between inhibiting
monocyte and macrophage cytokines and its co-stimulating
effect on the T cells.[32] Unfortunately, there are no data on CSF
cytokine levels in patients with PR/IRIS associated with CNS-TB
treated with anti-TNF-a monoclonal antibodies.
What the role of TNF-a antagonists in the management of
CNS-TB should be is currently unknown. However, given the
major difficulties posed by PR/IRIS despite high doses of
corticosteroids, anti-TNF-a monoclonal antibodies would ap-
pear to offer a reliable alternative. It is possible that their safety
profiles may even overcome the secondary effects associated with
repeated high doses of corticosteroids.
To date, the strategy of using adjunctive TNF-a antagonists
instead of corticosteroids to prevent CNS-TB-associated PR/IRIS
and improve outcomes has only been explored with thalidomide
in children with stage 2 and 3 TB meningitis. In an open-label
study with escalating thalidomide doses (6, 12, and 24mg/kg/
day) in South Africa,[33] clinical and neuroimaging outcomes
were better than previously observedwith historical controls, and
the thalidomide was well tolerated. The same group later
conducted a randomized, double-blinded, placebo-controlled
trial using doses of 24mg/kg/day.[32] However, the study was
terminated prematurely because all adverse events and deaths
occurred in the thalidomide arm. The authors concluded that the
results did not support the use of high doses of thalidomide as
adjunctive therapy for TBmeningitis in children. There have been
no similar studies among adults with CNS-TB, either using
thalidomide or using anti-TNF-a monoclonal antibodies, and
this is an area that warrants further research.
In conclusion, there is encouraging evidence on the potential
value of TNF-a antagonists in the management of CNS-TB and
deserves further evaluation in clinical trials.
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